Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

0 2

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“& ldquo; Regencell & rdquo; or the& ldquo; Company & rdquo;-RRB-, an

… Business Wire India Regencell Bioscience Holdings Limited(NASDAQ: RGC)(” & ldquo; Regencell & rdquo; or the & ldquo; Company & rdquo;-RRB-, an early-stage bioscience company that concentrates on research, advancement and commercialization of Traditional Chinese Medicine(& ldquo; TCM & rdquo;-RRB- for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder(& ldquo; ADHD & rdquo;-RRB- and Autism Spectrum Disorder(& ldquo; ASD & rdquo;-RRB-, today announced the pricing of its initial public offering (“& ldquo; Offering & rdquo;-RRB- of 2,300,000 ordinary shares at a public offering cost of$ 9.50 per ordinary share. The regular shares have been authorized for listing on the Nasdaq Capital Market and are anticipated to begin trading on July 16, 2021 under the ticker sign “& ldquo;

RGC. & rdquo; Regencell anticipates to get aggregate gross profits of approximately $21.9 million from this Offering, prior to subtracting underwriting discount rates and other associated expenses. In addition, the Company has approved the underwriters a 45-day choice to purchase as much as an additional 345,000 normal shares at the public offering cost, less underwriting discount rates. The Offering is expected to close on or about July 20, 2021, based on the complete satisfaction of traditional closing conditions.

Proceeds from the Offering will be used to fund the 2nd research study, the Company’& rsquo; s TCM solutions and items, staff incomes, centers rental, renovations and devices, item and copyright registrations, and working capital and other basic corporate functions. The Offering is being carried out on a firm commitment basis. Maxim Group LLC is serving as sole book-running-manager for the Offering.

Hunter Taubman Fischer & & Li LLC is serving as counsel to the Company, and Loeb & & Loeb LLP is functioning as counsel to Maxim Group LLC in connection with the Offering.

A registration declaration on Form F-1 associating with the Offering was filed with the Securities and Exchange Commission (“& ldquo; SEC & rdquo;-RRB-(File Number: 333-254571 )and was stated reliable by the SEC on July 15, 2021. The Offering is being made just by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus associating with the Offering might be gotten from Maxim Group LLC, 300 Park Ave, 16th Floor, New York, NY 10022, at (212) 895-3745. In addition, a copy of the prospectus associating with the Offering may be gotten via the SEC’& rsquo; s site at www.sec.gov. Prior to you invest, you should read the prospectus and other documents the Company has actually filed or will submit with the SEC for more total details about the Company and the Offering. This press release does not make up an offer to sell, or the solicitation of an offer to purchase any of the Company& rsquo

; s securities, nor will such securities be provided or sold in the United States missing registration or an applicable exemption from registration, nor will there be any offer, solicitation, or sale of any of the Company & rsquo; s securities in any state or jurisdiction in which such deal, solicitation, or sale would be illegal previous to registration or qualification under the securities laws of such state or jurisdiction. About Regencell Bioscience Holdings Limited Regencell Bioscience Holdings Limited is an early-stage bioscience company that concentrates on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. The Company started in Hong

Kong in 2014 and finished its first research study

utilizing individualized TCM formula in Hong Kong. The Company intends to introduce 3 liquid-based standardized TCM solutions prospects for moderate, extreme and moderate ADHD and ASD patients in Hong Kong initially and consequently to other markets as we consider proper. Positive Statements All declarations other than declarations of historical truth in this statement are forward-looking statements, consisting of however not restricted to, the Company & rsquo; s proposed Offering. These positive statements include understood and unknown dangers and unpredictabilities and are based upon current expectations and projections about future events and

financial patterns that the Company

thinks might impact its monetary condition, outcomes of operations, company strategy, and monetary needs, consisting of the expectation that the Offering will be successfully finished. Financiers can identify these positive statements by words or expressions..

The Company carries out no commitment to update positive declarations to reflect subsequent taking place events or” “circumstances, “or changes in” “its expectations,” “except as may be needed by law.” “” “the Company” “thinks that the expectations expressed in these positive declarations are reasonable, it can not assure you that such expectations will turn out to be right, and the Company warns investors that actual results may differ materially from the prepared for results and motivates investors to review other elements that may impact its future results in the Company & rsquo; s registration declaration and in its other filings with the SEC. View source version on businesswire.com: https://www.businesswire.com/news/home/20210715006080/en/

Leave A Reply